Hipoxemia y el riesgo de hipertensión arterial en apnea obstructiva del sueño / Hypoxemia and the Hypertension Risk in Obstructive Sleep Apnea

Hay poca información sobre el rol de la hipoxemia como factor de riesgo de hipertensión arterial (HTA) en pacientes con apnea obstructiva del sueño. El objetivo de este estudio fue evaluar la hipoxemia como factor de riesgo independiente de HTA en un modelo de trabajo basado en pacientes reales examinados en una unidad de sueño. Métodos: estudio retrospectivo. Modelo predictivo mediante regresión logística múltiple para establecer la relación entre HTA y edad, sexo, índice de masa corporal (IMC), índice de apneas e hipopneas por hora de registro (IAH) y tiempo de saturación de oxígeno debajo de 90% (T90 > 3%). Resultados: incluimos 3854 pacientes (edad mediana 55 años), predominio varones (61.5%). Según el modelo, las variables asociadas con HTA fueron: edad (OR 3.27 ­ 3.29, IC95% 2.83 ­ 3.80, p < 0.0001), sexo masculino (OR 1.35, IC95% 1.17 ­ 1.56, p < 0.001), obesidad (OR 1.83, IC95% 1.59 ­ 2.11, p < 0.0001), IAH ≥ 15 eventos por hora (OR 1.22, IC95% 1.05 ­ 1.43, p < 0.01) y T90 ≥ 3% (OR 1.56 ­ 1.57, IC95% 1.32 ­ 1.84, p < 0.0001). Conclusiones: en una población clínica con sospecha de apnea obstructiva del sueño, la hipoxemia (T90 ≥ 3%) se asoció con hipertensión arterial. (AU);

There is limited information about the role of hypoxemia degree as a risk factor for hypertension (HTN) in patients with obstructive sleep apnea (OSA). The objective of this study is to assess hypoxemia as an independent risk factor for HTN in a work model based on real-life patients examined at sleep unit. Methods: this retrospective study consisted of a predictive model using multiple logistic regression to establish the relationship between HTN and age, sex, body mass index (BMI), apnea/hypopnea index (AHI) and time below SO2 ≤ 90% (T90 ≥ 3%). Results: we included 3.854 patients (median age: 55 years), mostly men (61.5%). According to the model, the variables that were significantly associated with HTN were: age (OR: 3.27 ­ 3.29, CI95% 2.83 ­ 3.80, p < 0.0001), male sex (OR 1.35, CI95% 1.17 ­ 1.56, p < 0.001), Obesity (OR 1.83, CI95% 1.59 ­ 2.11, p < 0.0001), AHI > 15 events per hour (OR 1.22, CI95% 1.05 ­ 1.43, p < 0.01) and T90 ≥ 3% (OR 1.56 ­ 1.57, CI95% 1.32 ­ 1.84, p < 0.0001). Conclusion: in a clinical population of subjects suspected of OSA, nocturnal hypoxemia measure as T90 ≥ 3% was associated with HTN. (AU);

The Cervical Fat Tissue Volume is a Predictor for Moderate to Severe OSA.

Objective Obstructive sleep apnea (OSA) is a disorder characterized by recurrent pharyngeal obstruction during sleep, in which upper airway anatomy plays a key role in its pathogenesis. The aim of this study was to describe whether the quantification of cervical fat tissue volume (CFTV) obtained by Computed Tomography (CT)cephalometry is related to the severity of OSA. Methods Retrospective study between 2018 and 2020 in those patients > 18 years old, with diagnosis of OSA who performed a volumetric cephalometric imaging. Three-dimensional reconstruction of the images was performed and CFTV was measured. Results 91 patients were included in this study of which: without OSA (n: 7), mild (n: 19), moderate (n: 39) and severe OSA (n: 26). We observed a progressive increase of CFTV related to OSA severity has been observed (without OSA: 58.9 ml (47.9-87.5), mild: 59.1ml (48.4-78.3), moderate: 71 ml (42.6-127.1) and severe OSA 103.6 ml (81-153); p < 0.01); nevertheless, no differences were found in the airway volume and neck area. It was showed a significant correlation between CFTV and OSA indicators: AHI, ODI and T90 (Sp r: 0.48; 0.38 and 0.36; p < 0.01 respectively). CFTV cut-off value to discriminate AHI >15 ev/h with best sensitivity-specificity relationship was 64.1 ml with an area under the curve of 0.6 ± 0.06. Multivariate analysis showed that CFTV is a predictor for moderate to severe OSA (OR:3.05, IC95%: 1.14-8.17). Conclusion Cervical fat quantification by CT cephalometry correlates with OSA severity in adults. Fat volume > 64.1 ml increased more than three times the risk of OSA moderate to severe.

Performance of the NOSE Questionnaire in Mask Selection for Home CPAP Titration.

Introduction Many patients abandon CPAP treatment because they find the mask uncomfortable. Therefore, specialists may benefit from the predictive value of airway assessment tools. Objective To identify nasal ventilation failure through the Nasal Obstruction Symptom Evaluation (NOSE) scale in patients with obstructive sleep apnea (OSA) who undergo home-based auto-adjusting CPAP titration and to determine whether there is a correlation between NOSE score and the type of mask selected. Materials and Methods In this prospective correlational study, the NOSE scale was used in terms of mask selection and titration indicators. Patients were classified based on their NOSE score: > or < 50. Results We included 303 patients; 226 men (74.5%), BMI: 33.2 ± 6.1 kg/m 2 , neck circumference (cm): 42.8 ± 3.6 and Epworth (ESS) score: 9.2 ± 5.6, mild OSA: 12 (3.9%), moderate OSA: 127 (41.9%), and severe OSA: 164 (54.1%). The mean NOSE score was 24.3 ± 22.8 and 42 patients (13.8%) had NOSE scores > 50. Indicators for both groups were: compliance (5.9 ± 1.3 vs. 5.8 ± 1.4 hours) p: 0.41, therapeutic pressure (9.1 ± 2.0 vs. 8.8 ± 1.6 cm of H 2 O) p: 0.23, residual AHI (2.3 ± 1.8 vs. 2.8 ± 2.6 events/hour) p: 0.25, and leaks (20.5 ± 10.6 vs. 21.3 ± 10.7 liters/minute) p: 0.64. According to adjusted multiple regression, a NOSE of > 50 was not a predictor of mask selection. Conclusions A > 50 NOSE score was not a predictor of mask selection, and it was not correlated to titration performance.

[Life care of a cohort of patients with home chronic ventilatory support]. / Trayectoria vital de pacientes con soporte ventilatorio crónico domiciliario.

INTRODUCTION: Home mechanical ventilation in chronic respiratory failure improves quality of life and decreases hospitalizations. In order to know clinical characteristics, resource consumption and survival, we proposed an analysis of the vital trajectory during six years. METHODS: Descriptive and retrospective study. Information was obtained from the clinical history of the day hospital program. Kaplan Meier type survival curves were made. We included 100 patients, 57% men, age 65 ± 13 years and body mass index of 29.1 ± 8.6 kg/m2. Thirty had chronic obstructive pulmonary disease (COPD), 23 had amyotrophic lateral sclerosis, 18 obesity hypoventilation syndrome, other neuromuscular diseases in 16 cases, diaphragmatic dysfunction in 10, and chest wall restriction in 3 patients. Ninety-eight received non-invasive ventilation and two invasive cases through tracheostomy. 80% used spontaneous-timed mode (S/T); 14.6%, spontaneous (S); 4% average volume-assured pressure support ventilation (AVAPS) and 1.3% control pressure. Non-invasive compliance was: 7.8 ± 2.6 hours/day. RESULTS: After the start of home ventilation, hospitalizations were reduced (0.2, SD: 0.38 vs. 0.5 SD: 0.5, p < 0.001) and days of hospitalization per episode (5.14, SD: 17.7 vs. 10.45 SD: 16.69, p < 0.001). Median survival was two years with a better vital prognosis in COPD (3 years on average) vs. neuromuscular disease (< 2 years) p < 0.05. CONCLUSIONS: patients with home mechanical ventilation showed a reduction in the days of hospitalization after starting ventilation. Better survival was observed in COPD in relation to neuromuscular disease.

Introducción: La ventilación mecánica domiciliaria en insuficiencia respiratoria crónica, mejora calidad de vida y disminuye hospitalizaciones. Para conocer características clínicas, consumo de recursos y supervivencia, propusimos un análisis de la trayectoria vital durante seis años. Métodos: Estudio descriptivo y retrospectivo. Se obtuvo información de la historia clínica del programa de hospital de día. Se confeccionaron curvas de supervivencia tipo Kaplan Meier. Incluimos 100 pacientes, 57% hombres, edad 65 ± 13 años e índice de masa corporal de 29.1 ± 8.6 kg/m2. Treinta tenían enfermedad pulmonar obstructiva crónica (EPOC), 23 esclerosis lateral amiotrófica, 18 síndrome obesidad hipoventilación, otras enfermedades neuromusculares (ENM) en 16 casos, disfunción diafragmática en 10 y restricción por caja torácica en 3 pacientes. Noventa y ocho recibieron ventilación no invasiva y en dos casos invasiva mediante traqueostomía. El 80% utilizó modo spontaneous-timed (S/T); 14.6%, spontaneous (S); 4% average volume-assured pressure support ventilation ("AVAPS") y 1.3% presión control. El cumplimiento en no invasiva fue: 7.8 ± 2.6 horas/día. Resultados: Luego del inicio de la ventilación domiciliaria se redujeron las hospitalizaciones (0.2, DS: 0.38 vs. 0.5 DS: 0.5, p < 0.001) y los días de internación por episodio (5.14, DS: 17.7 "vs." 10.45 DS: 16.69, p < 0.001). La supervivencia media fue de dos años con mejor pronóstico vital en EPOC (3 años de media) vs. enfermedad neuromuscular (< 2 años) p < 0.05. Conclusiones: los pacientes con ventilación mecánica domiciliaria mostraron reducción de los días de hospitalización luego de comenzado el soporte ventilatorio. Se observó mejor supervivencia en EPOC en relación a enfermedad neuromuscular.

Trayectoria vital de pacientes con soporte ventilatorio crónico domiciliario / Life care of a cohort of patients with home chronic ventilatory support

Resumen Introducción: La ventilación mecánica domiciliaria en insuficiencia respiratoria crónica, mejora calidad de vida y disminuye hospitalizaciones. Para conocer características clínicas, consumo de recursos y supervivencia, propusimos un análisis de la trayectoria vital durante seis años. Métodos: Estudio descriptivo y retrospectivo. Se obtuvo información de la historia clínica del programa de hospital de día. Se confeccionaron curvas de supervivencia tipo Kaplan Meier. Incluimos 100 pacientes, 57% hombres, edad 65 ± 13 años e índice de masa corporal de 29.1 ± 8.6 kg/m2. Treinta tenían enfermedad pulmonar obstructiva crónica (EPOC), 23 esclerosis lateral amiotrófica, 18 síndrome obesidad hipoventilación, otras enfermedades neuromus culares (ENM) en 16 casos, disfunción diafragmática en 10 y restricción por caja torácica en 3 pacientes. Noventa y ocho recibieron ventilación no invasiva y en dos casos invasiva mediante traqueostomía. El 80% utilizó modo spontaneous-timed (S/T); 14.6%, spontaneous (S); 4% average volume-assured pressure support ventilation ("AVAPS") y 1.3% presión control. El cumplimiento en no invasiva fue: 7.8 ± 2.6 horas/día. Resultados: Luego del inicio de la ventilación domiciliaria se redujeron las hospitalizaciones (0.2, DS: 0.38 vs. 0.5 DS: 0.5, p < 0.001) y los días de internación por episodio (5.14, DS: 17.7 "vs." 10.45 DS: 16.69, p < 0.001). La supervivencia media fue de dos años con mejor pronóstico vital en EPOC (3 años de media) vs. enfermedad neuromuscular (< 2 años) p < 0.05. Conclusiones: los pacientes con ventilación mecánica domiciliaria mostraron reducción de los días de hospitalización luego de comenzado el soporte ventilatorio. Se observó mejor supervivencia en EPOC en relación a enfermedad neuromuscular.

Abstract Introduction: Home mechanical ventilation in chronic respiratory failure improves quality of life and decreases hospitalizations. In order to know clinical characteristics, resource consumption and survival, we pro posed an analysis of the vital trajectory during six years. Methods: Descriptive and retrospective study. Information was obtained from the clinical history of the day hospital program. Kaplan Meier type survival curves were made. We included 100 patients, 57% men, age 65 ± 13 years and body mass index of 29.1 ± 8.6 kg/m2. Thirty had chronic obstructive pulmonary disease (COPD), 23 had amyotrophic lateral sclerosis, 18 obesity hypoventilation syndrome, other neuromuscular diseases in 16 cases, diaphragmatic dysfunction in 10, and chest wall restriction in 3 patients. Ninety-eight received non-invasive ventilation and two invasive cases through tracheostomy. 80% used spontaneous-timed mode (S/T); 14.6%, spontaneous (S); 4% average volume-assured pressure support ventilation (AVAPS) and 1.3% control pressure. Non-invasive compliance was: 7.8 ± 2.6 hours/day. Results: After the start of home ventilation, hospitalizations were reduced (0.2, SD: 0.38 vs. 0.5 SD: 0.5, p < 0.001) and days of hospitalization per episode (5.14, SD: 17.7 vs. 10.45 SD: 16.69, p < 0.001). Median survival was two years with a better vital prognosis in COPD (3 years on average) vs. neuromuscular disease (< 2 years) p < 0.05. Conclusions: patients with home mechanical ventilation showed a reduction in the days of hospitalization after starting ventilation. Better survival was observed in COPD in relation to neuromuscular disease.

Ventilación no invasiva en sala de hospitalización general / Non-Invasive Ventilation in a Regular Hospital Ward

Introducción: La experiencia clínica ha permitido la ventilación no invasiva fuera de unidades críticas. Describimos el perfil clínico y evolución de pacientes que recibieron ventilación no invasiva en sala general. Material y métodos: Estudio retrospectivo en pacientes con soporte ventilatorio du rante un año en un hospital general. Resultados: Se utilizó ventilación no invasiva en 43 pacientes, 67,4% con hipercap nia. La relación hombre/mujer fue 1:1. La edad y el IMC fueron 68,3 ± 12,4 años y 30,1 ± 12,3 kg/m2 y los diagnósticos principales, enfermedad pulmonar obstructiva crónica, enfermedad neuromuscular y obesidad-hipoventilación. Un tercio inició la ventilación no invasiva en la unidad de cuidados intensivos, y dos tercios usaban ventilación no invasiva en domicilio antes del ingreso por exacerbación de la enfermedad pulmonar obstructiva crónica (39,5%) o progresión de la enfermedad (14%). La estancia hospi talaria fue 12,1 ± 7 d (14 ± 9 en supervivientes y 5,7 ± 3 en pacientes fallecidos). La gasometría arterial al ingreso reveló PaCO2: 52,7 ± 13,7 mmHg; PaO2: 72,2 ± 16,2 mmHg y pH de 7,36 ± 0,08. Se halló pH < 7,35 en el 18,6% y PaCO2 > 45 en el 57,4%. La PaCO2 al alta fue menor (46,1 ± 4,6; p > 0,05). El modo ST se utilizó en 34 (79%) pacientes. El período de ventilación fue 12,7 ± 10,2 días con uso de 6,9 ± 3,1 h/d. Un tercio recibió cuidados paliativos (13,9% de mortalidad). Tres pacientes (7%) fueron transferidos a la unidad de cuidados intensivos por deterioro clínico y treinta y cinco egresaron con ventilación crónica (94,6%). Conclusiones: Hubo escasas transferencias a la unidad de cuidados intensivos. La mortalidad hospitalaria fue baja y los que fallecieron tenían instrucciones anticipadas.

Introduction: Clinical experience has allowed the use of non-invasive ventilation out side the acute-care setting. We describe the clinical profile and evolution of patients who received non-invasive ventilation in a regular ward. Materials and methods: Retrospective study in patients with ventilatory support for one year in a general hospital. Results: Non-invasive ventilation was delivered to 43 patients, 67.4% of which had hy percapnia. The male/female ratio was 1:1. Age and BMI (Body Mass Index) were 68.3 ± 12.4 years and 30.1 ± 12.3 kg/m2, and the main diagnoses were chronic obstructive pulmonary disease, neuromuscular disease and obesity-hypoventilation. One third of patients began non-invasive ventilation in the Intensive Care Unit, and two thirds had been using non-invasive ventilation at their homes before being admitted with exacerba tion of chronic obstructive pulmonary disease (39.5%) or disease progression (14%). Hospital length of stay was 12.1 ± 7 d (14 ± 9 in survivors and 5.7 ± 3 in deceased patients). Arterial blood gas analysis on admission showed: PaCO2 (partial pressure of arterial carbon dioxide), 52.7 ± 13.7 mmHg; PaO2 (partial pressure of arterial oxygen), 72.2 ± 16.2 mmHg, and pH, 7.36 ± 0.08. A pH level < 7.35 was found in 18.6%, and PaCO2 > 45 in 57.4%. PaCO2 values upon discharge were lower (46.1 ± 4.6; p > 0.05). The ST (spontaneous-timed) mode was used in 34 patients (79%). The ventilation period was 12.7 ± 10.2 days, using 6.9 ± 3.1 h/d. One third of patients received palliative care (13.9% of mortality). Three patients (7%) were transferred to the Intensive Care Unit due to clinical decline, and thirty-five were discharged with chronic ventilation (94.6%). Conclusions: there were few referrals to the Intensive Care Unit. Hospital mortality was low, and patients who died had advance directives.

Asma grave y de difícil control

Resumen Introducción: El objetivo de este artículo es describir características, comorbilidades y fenotipos de pacientes con asma grave (AG) y asma de difícil control (ADC). Materiales y métodos: Estudio descriptivo trasversal de pacientes evaluados en el Consultorio de Asma de Difícil Control en el Hospital Británico en el período de un año. Se registró la edad, género y datos antropométricos, edad de diagnóstico, VEF1 al comienzo del seguimiento y exacerbaciones previas. Se evaluó control de síntomas con cuestionarios de Asthma Control Test y Asthma Control Quiestionnarie. Se registraron comorbilidades y se evaluó el perfil inflamatorio de los pacientes según biomarcadores medidos en sangre y muestra de esputo inducido. Resultados: 40 pacientes 20 ADC y 20 AG, no hubo diferencias significativas entre la edad, IMC, edad de comienzo de síntomas, control de los síntomas ni VEF1 al comienzo del seguimiento. En los pacientes con AG eran más frecuentes las crisis. Las comorbi lidades más comúnmente halladas fueron la obesidad, SAHOS y enfermedad por reflujo gastroesofágico, los trastornos psiquiátricos fueron más frecuentes en AG. El fenotipo más frecuente hallado fuel el TH2 alérgico. Discusiones y conclusión: no resulta fácil la clasificación en ambos grupos y muchas veces se encuentran con características solapadas. Las comorbilidades son frecuentes en ambos grupos siendo la obesidad, el SAHOS y la enfermedad por reflujo las más frecuentes. Lograr identificar el fenotipo de asma para dirigir el tratamiento.

Difficult-to-Treat and Severe Asthma

Abstract Introduction: The purpose of this article is to describe the characteristics, comorbidities and phenotypes of patients with difficult-to-treat asthma (DTA) and severe asthma (SA). Materials and Methods: Descriptive, cross-sectional study of patients evaluated at the Difficult-to-Treat Asthma Clinic of the Hospital Británico within the period of one year. We registered the age, gender and anthropometric data, age of diagnosis, FEV1 at the beginning of follow-up and previous exacerbations. We evaluated symptom control with the Asthma Control Test and the Asthma Control Questionnaire. We registered the comorbidities and evaluated the inflammatory profile of patients according to blood biomarker measurements and induced sputum sample. Results: Forty patients, 20 DTA and 20 SA. There weren't any significant differences regarding age, BMI, age of onset of symptoms, symptom control or FEV1 at the beginning of follow-up. Crises were more common in SA patients. The most commonly found co morbidities were obesity, OSAHS and gastroesophageal reflux disease. Psychiatric disorders were more common in SA patients. The most commonly found phenotype was allergen-reactive TH2. Discussion and Conclusion: it is not easy to classify both groups, and many times there are overlapping characteristics. Comor bidities are frequent in both groups: obesity, OSAHS and reflux disease are the most common conditions. Being able to identify the asthma phenotype in order to target the treatment.

Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.

BACKGROUND: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. RESEARCH QUESTION: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? STUDY DESIGN AND METHODS: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). RESULTS: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). INTERPRETATION: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. CLINICAL TRIALS REGISTRATION: NCT04521322.

Contribution of pulse oximetry in relation to respiratory flow events in a home-based approach aimed at diagnosing obstructive sleep apnea.

OBJECTIVE: To compare pulse oximetry with manual analysis against all signals of respiratory polygraphy. MATERIAL AND METHODS: This retrospective study estimated sensitivity (S), specificity (Sp) and positive/negative likelihood ratio (LR+/-) of the oxygen desaturation index (ODI-test) and apnea-hypopnea index (AHI-reference). RESULTS: 3854 patients (61.5% men) were included. Age, BMI, Epworth sleepiness scale and AHI were: 55 years (44-65), 30.9kg/m2 (27-36), 7 points (4-11), and 14 events/hour (6-25), respectively. 18% showed an AHI <5 events/hour, 34% = 5 and <15, 27% = or > 15 and < 30, and 31% > 30. The S, Sp, and LR+/- of ODI for AHI = 5 events/hour was 93%, 92%, 12 and 0.08 with an accuracy of 93%. For AHI = 15 events/hour, the values were: S 94%, Sp 94%, LR+ 15 and LR- 0.06 and 94% accuracy (r(2) Spearman: 0.92). CONCLUSION: In a population at a high risk for OSA, home-based pulse oximetry had a diagnostic accuracy > 90% when is compared against all respiratory signals obtained from simplified home sleep testing.

Cumplimiento e intolerancias durante el tratamiento con presión positiva en las vías aéreas Perfil de consultas externas en una unidad de sueño

Resumen Introducción: El tratamiento con presión positiva puede generar efectos adversos. Para conocer el perfil de cumplimiento e intole rancias analizamos conductas instituidas por kinesiólogos de una Unidad de Sueño. Material y Métodos: Estudio retrospectivo, trasversal y observacional. Se incluyeron pacientes > 18 años con presión positiva derivados a la consulta kinésica. Resultados: Durante cuatro años se evaluaron 244 pacientes; 165 hombres (67%), edad; 65.7 ± 11.6 años, IMC (kg/m2) 31.0 ± 5.4, de los cuales 61% utilizaba CPAP fija, 29% autoajustable, 8% dispositivos binivelados, máscaras nasales 147 (60%), oronasales 52 (21%); almohadillas 37 (15%) y termohumidificador 92 (36%). Los motivos de consultas fueron; control de la terapia (239; 61%), intolerancias (67; 17%) y calibración (51; 13%). El cumplimiento (horas/noche) fue de 4.61 ± 2.1 con un % de noches > 4 horas de 67 ± 36 %. No hallamos diferencias de cumplimiento entre primer y segundo año (4.5 vs. 5.0 horas/noche) p > 0.13, aunque este fue mayor a partir de 600 días de uso de la terapia (p < 0.05). 141 pacientes (57%) presentaban dificultades siendo más frecuentes las fugas (19%) o intolerancias a la máscara (10%). Un (97%) de los pacientes resolvieron intolerancias con 194 conductas; demostración de máscaras (94; 48%), calibración (44; 22%), educación (45; 23%), titulación (13; 6%) y derivación al neumonólogo (14; 7%). Conclusiones: Dos terceras partes de los pacientes cumplen el tratamiento con presión positiva y la mitad presenta intolerancias. La consulta kinésica especializada puede contribuir a la identificación y resolución de dificultades durante la terapia.

Patient Intolerance and Compliance with Positive Airway Pressure Treatment Outpatient Consultations Profile in a Sleep Unit

Abstract Introduction: Treatment with positive pressure may cause adverse effects. In order to know the compliance and intolerance profile, we analyzed the behaviors established by physiotherapists of a Sleep Unit. Materials and Methods: Observational, retrospective, cross-sectional study. We included patients older than 18 years with positive pressure referred to the kinesiological consultation. Results: 244 patients were evaluated during four years: 165 men (67%), age 65.7 ± 11.6 years, BMI (Body Mass Index) 31.0 ± 5.4 (kg/m2), 61% of which used fixed CPAP (Continuous Positive Airway Pressure), 29% auto-adjusting CPAP, 8% bilevel devices, 147 (60%) nasal masks, 52 (21%) oronasal masks; 37 pads (15%), and 92 (36%) thermohumidifiers. Reasons for consultation were: therapy control, 239 (61%); intolerance, 67 (17%), and calibration, 51 (13%). Compliance (hours/night) was 4.61 ± 2.1, with a percentage of nights > 4 hours of 67 ± 36%. We didn't find any difference in the com pliance of the first and the second year (4.5 vs. 5.0 hours/night) p > 0.13, but the value was higher after 600 days of therapy (p < 0.05). 141 patients (57%) showed some complications, the most frequent being leaks (19%) or intolerance to the masks (10%). 97% of the patients resolved the intolerance with 194 behaviors: explanation of how to use the mask, 94 (48%); calibration, 44 (22%); information, 45 (23%); titration, 13 (6%), and referral to the pulmonologist, 14 (7%). Conclusions: Two thirds of the patients complied with the positive pressure treatment and half of the patients showed intolerance. The specialized kinesiological consultation can contribute to the identification and resolution of difficulties that may arise during therapy.

Compliance to Continuous Positive Airway Pressure therapy in patients with obstructive sleep apnea - long-term assessment.

INTRODUCTION: To assess CPAP acquirement, compliance, and dropout rates among OSA patients three years after the prescription. MATERIAL AND METHODS: We assessed CPAP acquirement (Acq), compliance (Comp), and dropout (Dout) through a telephone survey. We interviewed 156 patients; ESS: 9.9±5.7, AHI>15ev/hour in 96.4%. 92 patients had accessed CPAP therapy (58.9%) and 67 (72.8%) were still using it. Dropout was reported by 25 (27.2%). The Comp group was older (p<0.01), had more men (p<0.001), higher ESS scores (p<0.03) and a higher level of specialist follow-up (p<0.001). Multivariate analysis adjusted showed; follow-up by experts (OR: 4.39; p<0.05) and ESS>10 (OR: 1.25; p<0.05) increased CPAP compliance. CONCLUSION: There is a high number of patients without CPAP therapy acquirement. Long-term compliance was found in ¾ of the study population in symptomatic patients followed up by specialists. Finally, 43% had effective treatment.

[Prevalence and characteristics of obstructive sleep apneas according to severity]. / Prevalencia y características de apneas obstructivas de sueño según gravedad.

Obstructive sleep apnea (OSA) is a prevalent condition. OSA is defined as very severe when the apneas/ hypopneas index (AHI) is greater than 60 events/hour. However, its prevalence remains uncertain. The aim of this study was to describe the prevalence and characteristics from patients with OSA according to severity. We performed a retrospective analysis of patients > 18 years, assessed by respiratory polygraph. We evaluated a total of 5670 patients with a mean of age of 54.4 ± 14.3 years old, of which 3606 were included in the OSA group. The overall prevalence of very severe OSA was 4.8%, being higher in men than in women (6.8 vs 1.9%). This group of patients was younger than the less severe groups (54.7 ± 13.9: mild OSA; 56.5 ± 12.9: moderate OSA; 57.9 ± 13.0: severe OSA vs 51.5 ± 12.9 years in the very severe patients; p < 0.0001). The results showed a significant increase in the body mass index (BMI) of patients with very severe OSA (31.6 ± 6.9: mild OSA, 32.8 ± 6.6: moderate OSA, 34.0 ± 6.8 severe OSA vs 37.1 ± 8.5 extreme severity; p < 0.0001), with similar results in men, but not in women. Finally, drowsiness due to ESS > 10, showed a significant increase in the very severe group of both sexes; 43.2% vs 31.5% (severe OSA); 26.4% (moderate OSA) and 23.8% (mild OSA). Very severe OSA presented a prevalence of 4.8% of patients with OSA. According to previous publications in other studied populations, we found that patients with very severe OSA are younger and more obese than the less severe groups.

La apnea obstructiva del sueño (AOS) constituye una afección prevalente. Se define AOS muy grave cuando el índice de apneas/hipopneas (IAH) es mayor a 60 eventos/hora. Sin embargo, su prevalencia sigue siendo incierta. El objetivo de este estudio fue d escribir la prevalencia y características de pacientes con AOS según la gravedad. Se realizó un análisis retrospectivo de pacientes > 18 años, evaluados mediante poligrafía respiratoria. Fueron evaluados 5670 de los cuales se incluyeron 3606 pacientes con AOS, con una media de edad de 54.4 ± 14.3 años. La prevalencia global de AOS muy grave fue de 4.8%, siendo mayor en hombres que en mujeres (6.8 vs. 1.9). Este grupo resultó más joven que los grupos de menor gravedad (54.7 ± 13.9: AOS leve; 56.5 ± 12.9: AOS moderado; 57.9 ± 13.1: AOS grave vs. 51.5 ± 12.9 años en los muy graves; p < 0.0001). Los resultados mostraron un aumento significativo del índice de masa corporal en aquellos con AOS muy grave (31.6 ± 6.9: AOS leve, 32.8 ± 6.6: AOS moderado, 34.0 ± 6.8 AOS grave vs. 37.1 ± 8.5 de gravedad extrema; p < 0.0001), con resultados similares en hombres, pero no en mujeres. Finalmente, la somnolencia por ESS > 10, mostró un aumento significativo en el grupo muy graves de ambos sexos; 43.2% vs. un 31.5% (AOS grave); 26.4% (AOS moderado) y un 23.8% (AOS leve). El AOS muy grave presenta una prevalencia del 4.8% de los pacientes con AOS. En acuerdo con publicaciones previas en otras poblaciones estudiadas, encontramos que los pacientes con AOS muy graves, son más jóvenes y obesos que los grupos de menor gravedad.

Asociación entre aldosterona plasmática y apneas del sueño en hipertensión arterial / Association between plasma aldosterone and sleep apneas and arterial hypertension

RESUMEN Introducción: La hipertensión arterial y las apneas e hipopneas obstructivas del sueño son patologías de alta prevalencia frecuentemente relacionadas, fundamentalmente en pacientes con hipertensión arterial resistente. En los pacientes con esta afección, los niveles de aldosterona se correlacionan con la gravedad de la apnea obstructiva del sueño y su bloqueo reduce la gravedad. Se ha afirmado que la apnea obstructiva del sueño podría aumentar la secreción de esta hormona y que este podría llegar a ser uno de los mecanismos involucrados en el aumento de la presión arterial. Sin embargo, poca evidencia demuestra su relación con la gravedad de la apnea obstructiva del sueño en la población con sospecha de hipertensión arterial. Objetivo: Determinar la asociación entre aldosterona plasmática y la apnea obstructiva del sueño en pacientes con sospecha de hipertensión arterial sin tratamiento farmacológico. Material y método: Se diseñó un estudio prospectivo, observacional y descriptivo. El diagnóstico de hipertensión arterial se realizó mediante monitoreo ambulatorio de la presión arterial. La sospecha clínica de apnea obstructiva del sueño fue evaluada mediante poligrafía respiratoria domiciliaria autoadministrada y se definió gravedad según el índice de apneas e hipopneas por hora de registro. La medición de aldosterona plasmática se realizó en una extracción matinal en la misma evaluación. Resultados: Se incluyeron 109 pacientes. La apnea obstructiva del sueño presentó mayor nivel basal de aldosterona independientemente que fuesen o no hipertensos (p < 0,05) y existió un incremento escalonado a medida que aumentaba la gravedad de la apnea obstructiva del sueño en pacientes normotensos (p < 0,05), mientras que, en el grupo de hipertensión arterial, se halló el mismo patrón, pero sin diferencias significativas. Conclusión: Se pudo observar un aumento proporcional de los valores de aldosterona, glucemia y riesgo cardiovascular a medida que se incrementaba la gravedad de la apnea del sueño.

ABSTRACT Background: Hypertension and obstructive sleep apneas and hypopneas are highly prevalent, frequently associated diseases, mainly in patients with resistant hypertension. In these patients, aldosterone levels correlate with obstructive sleep apnea severity and its blockade reduces seriousness. It has been reported that obstructive sleep apnea could intensify aldosterone secretion and this could be one of the mechanisms that increase blood pressure. However, there is little evidence demonstrating its relationship with the severity of obstructive sleep apnea in the population with suspected hypertension. Objective: The aim of this study was to establish the association between plasma aldosterone and obstructive sleep apnea in patients with suspected hypertension without pharmacological treatment. Methods: This was a prospective, descriptive observational study. Hypertension was diagnosed by ambulatory monitoring of blood pressure. The clinical suspicion of obstructive sleep apnea was evaluated by self-administered home respiratory polygraphy and severity was defined according to the apnea-hypopnea index per registry hour. Plasma aldosterone was assessed from a morning blood sample in the same evaluation session. Results: A total of 109 patients were included in the study. Baseline aldosterone was higher in patients with obstructive sleep apnea independently of whether they were or not hypertensive (p <0.05). A stepwise aldosterone increase was found as obstructive sleep apnea was more severe in normotensive patients (p <0.05), while in the hypertensive group, the same pattern was found, but without significant differences. Conclusion: A proportional increase in aldosterone, blood glucose and cardiovascular risk was found with increased sleep apnea severity.

Sarcoidosis: análisis de 24 casos

La sarcoidosis es una enfermedad inflamatoria granulomatosa sistémica de etiología desconocida y con incidencia variable. Con el objetivo de describir la presentación clínica de un grupo de pacientes con diagnóstico de sarcoidosis en un hospital de comunidad, se realizó la revisión de las historias clínicas de los pacientes con diagnóstico compatible con sarcoidosis desde 2007 hasta 2017. En este período se incluyeron 24 pacientes, al momento de la presentación se encontraban de acuerdo a la radiología en estadio I el 75% de los casos, en el II el 5%, estadio III el 10% y 10% en estadio IV. Recibieron tratamiento el 60% de los pacientes. En este estudio se describen las características de los pacientes con la finalidad de contribuir a identificar esta entidad y optimizar su diagnóstico y manejo temprano.

Sarcoidosis: Analysis of 24 cases

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology and variable incidence. For the purpose of de­scribing the clinical presentation of a group of patients diagnosed with sarcoidosis in a community hospital, we reviewed the medical records of patients whose diagnosis was consistent with sarcoidosis between 2007 and 2017. In this period, 24 patients were included and staged at presentation according to radiological data, showing that 75% were Stage I, 5% stage II, 10% stage III, and 10% stage IV. 60% of patients were treated. This study describes the patients' characteristics with the aim of helping to identify this entity and optimize early diagnosis and treatment.

Normativa: técnica de esputo inducido en enfermedades inflamatorias broncopulmonares / Technical Guidelines for Induced Sputum in Bronchopulmonary Inflammatory Diseases

Las enfermedades broncopulmonares se asocian a diversos mecanismos inflamatorios de las vías aéreas. Evaluar y comprender el perfil inflamatorio de estos pacientes podría contribuir a conocer la etiología y así optimizar el tratamiento. El esputo inducido es una técnica mínimamente invasiva, por lo que su implementación resulta de interés en la práctica habitual. Aunque el estudio del esputo inducido ha demostrado utilidad y seguridad, los centros que desarrollan esta técnica en la Argentina son escasos. Con el objetivo de estandarizar el procedimiento de recolección y análisis de muestras de esputo inducido en pacientes con enfermedades inflamatorias broncopulmonares, se desarrolló esta guía consensuada por los centros con experiencia en esta técnica en nuestro país. Es nuestra intención difundir esta técnica, mínimamente invasiva, para su aplicación en servicios especializados. Esta guía de procedimientos detalla los materiales que son requeridos, los métodos y los estándares de calidad y seguridad tanto para los pacientes como para los operadores.

Bronchopulmonary diseases are associated with different inflammatory mechanisms of the airways. Assessing and understanding the inflammatory profile of these patients could contribute to the understanding of the etiology and thus optimize the treatment. Induced sputum is a minimally invasive technique, so its implementation is of interest in the usual practice. Although the studies of induced sputum have shown usefulness and safety, the centers that develop this technique in Argentina are scarce. With the aim of standardizing the procedure that includes the collection and analysis of induced sputum samples in patients with bronchopulmonary inflammatory diseases, some centers in our country with experience in this technique achieved a consensus on the development of this Guide. It is our intention to disseminate this minimally invasive technique for its application in specialized services. This procedure guide details the necessary materials and methods and quality and safety standards for both patients and operators.

[Secondary syphilis with pulmonary involvement]. / Sífilis secundaria con compromiso pulmonar.

We present the case of a 62-year-old woman who consulted for fever (38°), stabbing thoracic pain (on one side), and pruritic skin lesions. She underwent peripheral blood tests, chest X-rays and CT. Her symptoms were interpreted as severe communityacquired pneumonia. After a treatment with antibiotics, her skin lesions persisted, and other symptoms were only partially relieved. A skin biopsy was performed, which revealed Treponema pallidum. Such finding was confirmed through positive serum VDRL and FTA-ABS tests. The patient received 4 doses of benzathine penicillin G with favorable evolution of skin lesions and improvement of radiological images.

La sífilis es una enfermedad de transmisión sexual causada por una espiroqueta, Treponema palidum. Presentamos el caso de una mujer de 62 años de edad, que consultó por fiebre de 38°, dolor torácico en puntada de costado y lesiones pruriginosas en piel. Se realizó examen de laboratorio de sangre periférica, radiografía y tomografía de tórax. Recibió tratamiento antibiótico y fue diagnosticada como neumonía aguda de la comunidad. Debido a la respuesta parcial de los síntomas y persistencia de lesiones pruriginosas se realizó biopsia de piel que informó Treponema palidum, el cual fue confirmado con test serológico VDRL y FtA-abs positivo. La paciente recibió 4 dosis de penicilina G benzatínica con favorable evolución de las lesiones en piel y mejoría de las imágenes radiológicas.

Sífilis secundaria con compromiso pulmonar / Secondary syphilis with pulmonary involvement

La sífilis es una enfermedad de transmisión sexual causada por una espiroqueta, Treponema palidum. Presentamos el caso de una mujer de 62 años de edad, que consultó por fiebre de 38°, dolor torácico en puntada de costado y lesiones pruriginosas en piel. Se realizó examen de laboratorio de sangre periférica, radiografía y tomografía de tórax. Recibió tratamiento antibiótico y fue diagnosticada como neumonía aguda de la comunidad. Debido a la respuesta parcial de los síntomas y persistencia de lesiones pruriginosas se realizó biopsia de piel que informó Treponema palidum, el cual fue confirmado con test serológico VDRL y FtA-abs positivo. La paciente recibió 4 dosis de penicilina G benzatínica con favorable evolución de las lesiones en piel y mejoría de las imágenes radiológicas.

We present the case of a 62-year-old woman who consulted for fever (38°), stabbing thoracic pain (on one side), and pruritic skin lesions. She underwent peripheral blood tests, chest X-rays and CT. Her symptoms were interpreted as severe community-acquired pneumonia. After a treatment with antibiotics, her skin lesions persisted, and other symptoms were only partially relieved. A skin biopsy was performed, which revealed Treponema pallidum. Such finding was confirmed through positive serum VDRL and FTA-ABS tests. The patient received 4 doses of benzathine penicillin G with favorable evolution of skin lesions and improvement of radiological images.